Half-Life Cancer Research Results
Half-Life, Half-Life: Click to Expand ⟱
| Source: |
| Type: |
For many drugs, the half-life is the time it takes for half of the drug’s active substance to be eliminated from the bloodstream.
In medicine, knowing a drug’s half-life helps in designing treatment regimens that reduce adverse effects.
|
NA, Not Available: Click to Expand ⟱
Scientific Papers found: Click to Expand⟱
*COX1↓, *COX2↓, *cardioP↑, *BioAv↑, *BioAv↝, *Half-Life↓, Risk↓, *other↑, *AntiAg↑,
*antiOx↑, *Inflam↓, AntiTum↑, *BioAv↓, *Half-Life↓, *BioAv↝, *BioAv↓,
*BioAv↓, *Half-Life↓,
*P-gp↓, *Inflam↓, *hepatoP↑, *antiOx↑, *GSH↑, *BioAv↑, *SOD↑, *IFN-γ↓, *IL4↓, *IL10↓, *Half-Life↓, *TNF-α↓, *ALAT↓, *AST↓, Akt↓, chemoP↑, β-catenin/ZEB1↓, TumCP↓, MMP↓, Cyt‑c↑, *RenoP↑, *BBB↑,
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
Showing Research Papers: 1 to 5 of 5
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
ROS↓, 1,
Mitochondria & Bioenergetics ⓘ
ATP↓, 1, MMP↓, 2,
Core Metabolism/Glycolysis ⓘ
SIRT1↓, 1, SREBP1↓, 1,
Cell Death ⓘ
Akt↓, 1, Casp↑, 1, Cyt‑c↑, 2, p27↑, 1, Telomerase↓, 1,
Transcription & Epigenetics ⓘ
HATs↑, 1,
Cell Cycle & Senescence ⓘ
CDK4↓, 1, P21↑, 1, TumCCA↑, 1,
Proliferation, Differentiation & Cell State ⓘ
CD44↓, 1, EMT↓, 1, ERK↓, 1, HDAC↓, 1, IGFBP3↑, 1, NOTCH↓, 1, STAT3↓, 1, TumCG↓, 1, Wnt↓, 1,
Migration ⓘ
CA↓, 1, Ca+2↑, 1, E-cadherin↑, 1, FAK↓, 1, miR-203↑, 1, MMP2↓, 1, MMP9↓, 1, PDGF↓, 1, TGF-β↓, 1, TumCMig↓, 1, TumCP↓, 1, uPA↓, 1, Vim↓, 1, Zeb1↓, 1, β-catenin/ZEB1↓, 1,
Angiogenesis & Vasculature ⓘ
angioG↓, 1, EGFR↓, 1, Hif1a↓, 1, VEGF↓, 2,
Barriers & Transport ⓘ
NHE1↓, 1,
Immune & Inflammatory Signaling ⓘ
COX2↓, 1, IL1↓, 1, NF-kB↓, 1, PD-L1↓, 1, PGE2↓, 1, PSA↓, 1,
Hormonal & Nuclear Receptors ⓘ
AR↓, 1,
Drug Metabolism & Resistance ⓘ
BioAv↓, 3, Dose↝, 1, eff↝, 1, Half-Life↓, 1, Half-Life↝, 1, selectivity↑, 1,
Clinical Biomarkers ⓘ
AR↓, 1, EGFR↓, 1, PD-L1↓, 1, PSA↓, 1,
Functional Outcomes ⓘ
AntiCan↑, 1, AntiTum↑, 1, cardioP↑, 1, chemoP↑, 2, hepatoP↑, 1, Risk↓, 1, toxicity↝, 1, toxicity∅, 1,
Total Targets: 68
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress ⓘ
antiOx↑, 3, GSH↑, 1, SOD↑, 1,
Core Metabolism/Glycolysis ⓘ
ALAT↓, 1, SIRT1↑, 1,
Transcription & Epigenetics ⓘ
other↑, 1,
Migration ⓘ
AntiAg↑, 1, TIMP1↓, 1,
Barriers & Transport ⓘ
BBB↑, 1, P-gp↓, 1,
Immune & Inflammatory Signaling ⓘ
COX1↓, 1, COX2↓, 1, IFN-γ↓, 1, IL10↓, 1, IL4↓, 1, IL8↓, 1, Inflam↓, 3, TNF-α↓, 1,
Drug Metabolism & Resistance ⓘ
BioAv↓, 3, BioAv↑, 2, BioAv↝, 2, Half-Life↓, 4,
Clinical Biomarkers ⓘ
ALAT↓, 1, AST↓, 1,
Functional Outcomes ⓘ
cardioP↑, 1, hepatoP↑, 1, RenoP↑, 1,
Total Targets: 27
Scientific Paper Hit Count for: Half-Life, Half-Life
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:0 Cells:% prod#:% Target#:1109 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid
Home Page